Gerwin Winter joined BeiGene in March 2021 as Senior Vice President, Head of Commercial, Europe. In this role, he is responsible for building and leading the commercial team in Europe and operations that will bring BeiGene’s innovative medicines to patients in Europe.

Mr. Winter has worked in the pharmaceutical industry for nearly three decades, with a strong focus on hematology and oncology. Most recently, Mr. Winter was Senior Vice President and Head of Europe for Portola Pharmaceuticals, building European operations from scratch from January 2019 through its acquisition by Alexion in late 2020. Previously, Mr. Winter served in a progression of several General Management roles at Celgene (six years) and Bristol-Myers Squibb (12 years) where he was responsible for multiple launches in hematology for Revlimid® (lenalidomid), Imnovid® (pomalidomid), Vidaza® (azacitidin), Sprycel® (dasatinib), and Abraxane® for breast, lung, and pancreatic cancer.

Mr. Winter founded “SAIL in Bhutan” in 2018, a non-profit healthcare organization, aiming to prevent gastric cancer in an entire country. He received a PharmD in pharmacy from the University of Munich, Germany, and a General Management MBA from CEDEP at INSEAD University of Fontainebleau, France.